Sandoz Canada debuts generic Revlimid

Sandoz Canada is introducing one of the first Revlimid (lenalidomide) generics in the Great White North. The Boucherville, Quebec-based subsidiary of Sandoz has launched the drug in six strengths in 21- and 28-count blister packages.

Sandoz Lenalidomide is indicated to treat patients with transfusion-dependent anemia caused by intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenic ab-normality, with or without additional cytogenic abnormalities. It also is indicated, in combination with dexamethasone, to treat multiple myeloma in patients ineligible for stem cell transplant. 

The company said Canada would be the fifth country in which it is commercializing the product. Sandoz said the generic would be distributed via the RevAid distribution program through which the branded product is distributed. 

“We are very proud to contribute to making life-enhancing medicines more accessible by launching affordable and effective generics like Sandoz Lenalidomide, by supporting healthcare providers and patients, and by ensuring reliable supply,” says Michel Robidoux, president and general manager of Sandoz Canada. “The millions of dollars in savings created by generics contribute to strengthening our healthcare system for all Canadians.”

The product is available in dosage strengths of 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg.